Cargando…
HMGB1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-κB pathway
Chemotherapy resistance is a main obstacle in the clinical chemotherapeutic treatment of multiple myeloma (MM). High-mobility group box 1 (HMGB1) has been revealed to be associated with the sensitivity of MM cells to chemotherapy, but how HMGB1 regulates chemotherapy resistance in MM has yet to be f...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120504/ https://www.ncbi.nlm.nih.gov/pubmed/34007314 http://dx.doi.org/10.3892/etm.2021.10137 |